Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7060562 | 1.00 | — | — | |
| SCHEMBL3262023 | 0.97 | SPHK2 (0.79) | — | |
| SCHEMBL1795496 | 0.97 | — | — | |
| SCHEMBL3989834 | 0.94 | — | — | |
| Hydrochloric Acid SCHEMBL3629984 | 0.92 | — | — | |
| Hydrochloric Acid SCHEMBL8556241 | 0.89 | SPHK2 (0.95) | — | |
| Hydrochloric Acid SCHEMBL7609128 | 0.89 | SPHK2 (0.95) | — | |
| Hydrochloric Acid SCHEMBL1736276 | 0.89 | SPHK2 (0.95) | — | |
| Hydrochloric Acid SCHEMBL7618006 | 0.89 | SPHK2 (0.95) | — | |
| Hydrochloric Acid SCHEMBL15173510 | 0.89 | SPHK2 (0.95) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1411 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119947556-A | Perovskite precursor solution, preparation method thereof and perovskite solar cell | 广东脉络能源科技有限公司 | 2025-05-06 | — | — | CN | claimed |
| CN-119604170-A | Defect-passivated perovskite solar cell and preparation method thereof | 北京工业大学 | 2025-03-11 | — | — | CN | claimed |
| CN-116761477-A | Method for inducing perovskite film to orient and nucleate and application | 浙江大学 | 2023-09-15 | — | — | CN | claimed |
| CN-113336709-B | Preparation method of N, N-dimethylacetamide | 上海立科化学科技有限公司 | 2022-06-03 | — | — | CN | claimed |
| CN-114380749-A | Preparation method of glyoxal | 广西金茂生物化工有限公司 | 2022-04-22 | — | — | CN | claimed |
| CN-216039344-U | Hydrogen chloride waste gas recycle device in imidazole aldehyde production | 珠海润都制药股份有限公司 | 2022-03-15 | — | — | CN | claimed |
| CN-113336709-A | Preparation method of N, N-dimethylacetamide | 上海立科化学科技有限公司 | 2021-09-03 | — | — | CN | claimed |
| CN-107973784-B | Synthesis method of fimasartan | 珠海市海瑞德生物科技有限公司 | 2021-08-24 | — | — | CN | claimed |
| CN-112159411-A | Trifluoromethyl substituted pyrimido [1,3] diaza compound and preparation method thereof | 南京工业大学 | 2021-01-01 | — | — | CN | claimed |
| WO-2020068665-A1 | USE OF COLLAGEN BINDING DOMAINS TO DELIVER PRODUCTS TO SKIN | FABIUS BIOTECHNOLOGY (US) | 2020-04-02 | — | — | WO | claimed |
| WO-2013011514-A1 | PROTEOLYTIC EXTRACT FROM BROMELAIN FOR THE TREATMENT OF CONNECTIVE TISSUE DISORDERS | MEDIWOUND LTD. (IL) | 2013-01-24 | — | — | WO | claimed |
| CN-102666496-A | New preparation method of 2- (2-N-butyl-4-hydroxy-6-methyl-pyrimidin-5-yl) -N, N-dimethylacetamide | BORYUNG PHARM | 2012-09-12 | — | — | CN | claimed |
| EP-1848541-A2 | METHOD AND DEVICE FOR OPHTHALMIC ADMINISTRATION OF ACTIVE PHARMACEUTICAL INGREDIENTS | Pharmalight Inc. (US) | 2007-10-31 | — | — | EP | claimed |
| WO-2007117352-A2 | TOPICAL THERAPEUTIC DELIVERY SYSTEM | MURAD HOWARD (US) | 2007-10-18 | — | — | WO | claimed |
| WO-2007092085-A2 | FRAGRANCED THERAPEUTIC DELIVERY SYSTEM | MURAD HOWARD (US) | 2007-08-16 | — | — | WO | claimed |
| WO-2006082588-A2 | METHOD AND DEVICE FOR OPHTHALMIC ADMINISTRATION OF ACTIVE PHARMACEUTICAL INGREDIENTS | PHARMALIGHT INC. (US) | 2006-08-10 | — | — | WO | claimed |
| US-5948416-A | LEAVE ON SKIN CARE COMPOSITION; HYDROPHOBIC STRUCTURING AGENT; HYDROPHILIC CATIONIC SURFACTANT; ACTIVE COMPOUND | THE PROCTER & GAMBLE COMPANY (US) | 1999-09-07 | — | — | US | claimed |
| US-5780049-A | Enhanced skin penetration system for improved topical delivery of drugs | RICHARDSON-VICKS INC. (US) | 1998-07-14 | — | — | US | claimed |
| US-5364615-A | Pentamidine administered in aerosol form for treatment of Pmeumonia | REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1994-11-15 | — | — | US | claimed |
| EP-0315467-A2 | Pentamidine salts useful in the treatment and prophylaxis of pneumocystis carinii pneumonia | LyphoMed, Inc. (US) | 1989-05-10 | — | — | EP | claimed |